NG2 proteoglycan-binding peptides target tumor neovasculature

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2869-2874

  Burg, Michael A ^a,b   Pasqualini, Renata ^a   Arap, Wadih ^a   Ruoslahti, Erkki ^a   Stallcup, William B ^a  

^a BURNHAM INSTITUTE   (United States)

^b Selective Genetics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; PEPTIDE LIBRARY; PROTEOGLYCAN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; TUMOR CELL; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS; BACTERIOPHAGES; GLUTATHIONE TRANSFERASE; HUMANS; LIGANDS; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDE LIBRARY; PROTEOGLYCANS; RATS; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0033564799     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
2. Folkman, J. Antiangiogenic therapy. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 3075-3085. Philadelphia: Lippincott-Raven, 1997.
3. Baillie, C. T., Winslet, M. C., and Bradley, N. J. Tumour vasculature: a potential therapeutic target. Br. J. Cancer, 72: 257-267, 1995.
4. Rak, J. W., St. Croix, B. D., and Kerbel, R. S. Consequences of angiogenesis for tumor progression, metastasis and cancer. Anticancer Drugs, 6: 3-18, 1995.
5. Derbyshire, E. J., and Thorpe, P. E. Targeting the tumour endothelium using specific antibodies. In: R Bicknell, C. E. Lewis, and N. Ferrara (eds.), Tumor Angiogenesis, pp. 343-356, 1998.
6. Burrows, F. J., and Thorpe, P. E. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA, 90: 8996-9000, 1993.
7. Arap, W., Pasqualini, R., and Ruoslahti, E. Chemotherapy targeted to tumor vasculature. Curr. Opin. Oncol., 10: 560-565, 1998.
8. Nishiyama, A., Dahlin, K. J., Prince, J. T., Johnstone, S. R., and Stallcup, W. B. The primary structure of NG2, a novel membrane-spanning proteoglycan. J. Cell Biol., 114: 359-371, 1991.
9. Pluschke, G., Vanek, M., Evans, A., Dittmar, T., Schmid, P., Itin, P., Filardo, E., and Reisfeld, R. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc. Natl. Acad. Sci. USA, 93: 9710-9715, 1996.
10. Behm, F. G., Smith, F. O., Raimondi, S. C., Pui, C-H., and Bernstein, I. D. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21; q23) or t(11;19)(q23;13) and MLL gene rearragements. Blood, 87: 1134-1139, 1996.
11. Real, F. X., Houghton, A. N., Albino, Cordon-Cardo, C., Melamed, M. R., Oettgen, H. F., and Old, L. J. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity, analysis, and comparison of antigen expression in cultured cells and tissues. Cancer Res., 45: 4401-4411, 1985.
12. Schrappe, M., Klier, F. G., Spiro, R. C., Waltz, T. A., Reisfeld, R. A., and Gladson, C. L. Correlation of chondroitin sulfate proleoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res., 51: 4986-4993, 1991.
13. Leger, O., Johnson-Leger, C., Jackson, E., Coles, B., and Dean, C. The chondroitin sulfate proteoglycan NG2 is a tumor specific antigen on the chemically induced rat chondrosarcoma HSN. Int. J. Cancer, 58: 700-705, 1994.
14. Bumol, T. F., Wang, Q. C., Reisfeld, R. A., and Kaplan, N. O. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc. Natl. Acad. Sci. USA, 80, 529-533, 1983.
15. Harper, J. R., and Reisfeld, R. A. Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proleoglycan. J. Natl. Cancer Inst. (Bethesda). 71: 259-263, 1983.
16. Harper, J. R., and Reisfeld, R. A. Cell-associated proteoglycans in human malignant melanoma. In: T. Wight and R. Mecham (eds.), Biology of Proteoglycans, pp. 345-366. New York: Academic Press, 1987.
17. Burg, M. A., Grako, K. A., and Stallcup, W. B. Expression of the NG2 proleoglycan enhances the growth and metastatic properties of melanoma cells. J. Cell. Physiol., 177: 299-312, 1998.
18. Nishiyama, A., and Stallcup, W. B. Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. Mol. Biol. Cell, 4: 1097-1108, 1993.
19. Burg, M. A., Tillet, E., Timpl, R., and Stallcup, W. B. Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J. Biol. Chem., 271: 26110-26116, 1996.
20. Burg, M. A., Nishiyama, A., and Stallcup, W. B. A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. Exp. Cell Res., 235: 254-264, 1997.
21. Tillet, E., Ruggiero, F., Nishiyama, A., and Stallcup, W. B. The membrane-spanning proteoglycan NG2 binds to collagen V and VI through the central non-helical portion of the ectodomain. J. Biol. Chem., 272: 10769-10776, 1997.
22. 1, integrin. Cancer Res., 55: 2177-2185, 1995.
23. Grako, K., and Stallcup, W. B. Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. Exp. Cell Res., 221: 231-240, 1995.
24. Nishiyama, A., Lin, X-H., Giese, N., Heldin, C-H., and Stallcup, W. B. Interaction between NG2 proteoglycan and PDGF a receptor is required for optimal response to PDGF. J. Neurosci. Res., 43: 315-330, 1996.
25. Schlingemann, R. O., Rietveld, F. J. R., de Waal, R. M. W., Ferrone, S., and Ruiter, D. J. Expression of the high molecular weight melanoma-associated antigen by pericyles during angiogenesis in tumors and in healing wounds. Am. J. Pathol., 136: 1393-1405, 1990.
26. Schlingemann, R. O., Rietveld, F. J., Kwaspen, F., van de Kerkhof, P. C., de Waal, R. M., and Ruiter, D. J. Differential expression of markers for endothelial cells, pericyles, and basal lamina in the microvasculature of tumors and granulation tissue. Am. J. Pathol., 138: 1335-1347, 1991.
27. Sims, D. E. The pericyte: a review. Tissue Cell, 18: 153-174, 1986.
28. Hirschi, K. K., and D'Amore, P. A. Control of angiogenesis by the pericyte: molecular mechanisms and significance. In: I. D. Goldberg and E. M. Rosen (eds.), Regulation of Angiogenesis, pp. 419-428. Basel, Switzerland: Birkhauser Verlag, 1997.
29. Lindahl, P., and Betsholtz, C. Not all myofibroblasts are alike: revisiting the role of PDGF-A and PDGF-B using PDGF-targeted mice. Curr. Opin. Nephrol. Hypertens., 7: 21-26, 1998.
30. Lindahl, P., Johansson, B. R., Leveen, P., and Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (Washington DC), 277: 242-245, 1997.
31. Yang, H. M., and Reisfeld, R. A. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc. Natl. Acad. Sci. USA, 85: 1189-1193, 1988.
32. Spitler, L. E., del Rio, M., Khentigan, A., Wedel, N. I., Brophy, N. A., Miller, L. L., Harkonen, W. S., Rosendorf, L. L., Lee, H. M., Mischak, R. P., Kawahata, R. T., Stoudemire, J. B., Fradkin, L. B., Bautista, E. E., and Scannon, P. J. Therapy of patients with malignant melanoma using a monoclonal anti-melanoma antibody-ricin immunotoxin. Cancer Res., 47: 1717-1723, 1987.
33. 2: a preliminary report. J. Neuro-Oncol., 24: 109-122, 1995.
34. Shockley, T. R., Lin, K., Nagy, J. A., Tompkins, R. G., Dvorak, H. F., and Yarmush, M. L. Penetration of tumor tissue by antibodies and other immunoproteins. Ann. N. Y. Acad. Sci., 618: 367-382, 1991.
35. Dvorak, H. F., Nagy, J. A., and Dvorak, A. M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3: 77-85, 1991.
36. Molema, G., de Leij, L. F., and Meijer, D. K. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm. Res., 14: 2-10, 1997.
37. Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. Microcirculation, 4: 3-23, 1997.
38. Koivunen, E., Wang, B., and Ruoslahti, E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. BioTechnology, 13: 265-270, 1995.
39. Koivunen, E., Restel, B., Rajotte, D., Lahdenranta, J., Hagedorn, M., Arap, W., and Pasqualini, R. Integrin-binding peptides from phage display peptide libraries. Integrin protocols. Methods Mol. Biol., in press, 1999.
40. 1 selected from a phage display library. J. Biochem., 120: 445-451, 1996.
41. Yanofsky, S. D., Baldwin, D. N., Butler, J. H., Holden, F. R., Jacobs, J. W., Balasubramanian, P., Chinn, J. P., Cwirla, S. E., Peters-Bhatt, E., Whitehorn, E. A., Tate, E. H., Adeson, A., Bowlin, T. L., Dower, W. J., and Barret, R. W. High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc. Natl. Acad. Sci. USA, 93: 7381-7386, 1996.
42. Popkov, M., Lussier, I., Medvedkine, V., Esteve, P-E., Alakhov, V., and Mandeville, R. Multidrug-resistance drug-binding peptides generated by using a phage display library. Eur. J. Biochem., 251: 155-163, 1998.
43. Pennington, M. E., Lam, K. S., and Cress, A. E. The use of a combinatorial library method to isolate human tumor cell adhesion peptides. Mol. Divers., 2: 19-28, 1996.
44. Goodson, R. J., Doyle, D. V., Kaufman, S. E., and Rosenberg, S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA, 91: 7129-7133, 1994.
45. Pasqualini, R., and Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature (Lond.), 380: 364-366, 1996.
46. Pasqualini, R., Koivunen, E., and Ruoslahti, E. αv integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol., 15: 542-546, 1997.
47. Rajotte, D., Arap, W., Hagedorn, M., Koivunen, E., Pasqualini, R., and Ruoslahti, E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest., 102: 430-437, 1998.
48. Smith, G. P., and Scott, J. K. Libraries of peptides and proteins displayed in filamentous phage. Methods Enzymol., 21: 228-257, 1993.
49. Grako, K. A., Ochiya, T. A., Barritt, D., Nishiyama, A., and Stallcup, W. B. PDGF α-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J. Cell Sci., 112: 905-915, 1999.
50. Blood, C. H., and Zetter, B. R. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta, 1032: 89-118, 1990.
51. Nagy, J. A., Brown, L. F., Senger, D. R., Lanir, N., Van de Water, L., Dvorak, A. M., and Dvorak, H. F. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim. Biophys. Acta, 948: 305-326, 1989.
52. Dvorak, H. F., Nagy, J. A., Dvorak, J. T., and Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133: 95-109, 1989.
53. Nowell, P. C. The clonal evolution of tumor cell populations. Science (Washington DC), 194: 23-28, 1976.
54. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays, 13: 31-36, 1991.
55. Kerbel, R. S. A cancer therapy resistant to resistance. Nature (Lond.), 390: 335-336, 1997.
56. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.